Abstract
Background: A hyperglycemic crisis episode (HCE) signifies poor control of diabetes and may increase the risk of dementia via microvascular and macrovascular injuries. Objectives: We conducted this study to clarify this issue, which remains unclear. Methods: Using the Taiwan National Health Insurance Database, we identified 9,466 diabetic patients with HCE and the identical number of diabetic patients without HCE who were matched by age and sex for this nationwide population-based cohort study. The risk of dementia was compared between the 2 cohorts by following up until 2014. Investigation of independent predictors of dementia was also done. Results: In the overall analysis, the risk of dementia between the 2 cohorts was not different. However, stratified analyses showed that patients with HCE had a higher risk of subsequent dementia in the age subgroup of 45−54 and 55–64 years (adjusted odds ratio [AOR]: 2.4, 95% confidence interval [CI]: 1.6–3.6, and AOR: 1.2, 95% CI: 1.0–1.5, respectively). In the overall analysis, older age, female sex, ≥3 HCEs, hypertension, hyperlipidemia, depression, cerebrovascular disease, Parkinson’s disease, and head injury were independent predictors. Conclusions: HCE increased the risk of dementia in diabetic patients aged 45–64 years. Dementia was predicted by ≥3 HCEs. Prevention of recurrent HCE, control of comorbidities, and close follow-up of cognitive decline and dementia are suggested in patients with HCE.
References
1.
Hay
SI
, Abajobir
AA
, Abate
KH
, Abbafati
C
, Abbas
KM
, Abd-Allah
F
, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016
. Lancet
. 2017
;390
(10100
):1260
–344
. 2.
Zhou
B
, Lu
Y
, Hajifathalian
K
, Bentham
J
, Di Cesare
M
, Danaei
G
, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants
. Lancet
. 2016
;387
(10027
):1513
–30
. 3.
Selvin
E
, Parrinello
CM
, Sacks
DB
, Coresh
J
. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010
. Ann Intern Med
. 2014
;160
(8
):517
–25
. 4.
Bullard
KM
, Cowie
CC
, Lessem
SE
, Saydah
SH
, Menke
A
, Geiss
LS
, et al. Prevalence of diagnosed diabetes in adults by diabetes type: United States, 2016
. Morb Mortal Wkly Rep
. 2018
;67
(12
):359
–61
. 5.
Xu
G
, Liu
B
, Sun
Y
, Du
Y
, Snetselaar
LG
, Hu
FB
, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study
. BMJ
. 2018
;362
:k1497
. 6.
Mayer-Davis
EJ
, Lawrence
JM
, Dabelea
D
, Divers
J
, Isom
S
, Dolan
L
, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012
. N Engl J Med
. 2017
;376
(15
):1419
–29
. 7.
Sheen
YJ
, Hsu
CC
, Jiang
YD
, Huang
CN
, Liu
JS
, Sheu
WH
. Trends in prevalence and incidence of diabetes mellitus from 2005 to 2014 in Taiwan
. J Formos Med Assoc
. 2019
;118
(Suppl 2
):S66
–73
. 8.
Rowley
WR
, Bezold
C
, Arikan
Y
, Byrne
E
, Krohe
S
. Diabetes 2030: insights from yesterday, today, and future trends
. Popul Health Manag
. 2017
;20
(1
):6
–12
. 9.
Huang
CC
, Kuo
SC
, Chien
TW
, Lin
HJ
, Guo
HR
, Chen
WL
, et al. Predicting the hyperglycemic crisis death (PHD) score: a new decision rule for emergency and critical care
. Am J Emerg Med
. 2013 May
;31
(5
):830
–4
. 10.
Huang
CC
, Weng
SF
, Tsai
KT
, Chen
PJ
, Lin
HJ
, Wang
JJ
, et al. Long-term mortality risk after hyperglycemic crisis episodes in geriatric patients with diabetes: a national population-based cohort study
. Diabetes Care
. 2015
;38
(5
):746
–51
. 11.
Chou
W
, Chung
MH
, Wang
HY
, Chen
JH
, Chen
WL
, Guo
HR
, et al. Clinical characteristics of hyperglycemic crises in patients without a history of diabetes
. J Diabetes Investig
. 2014
;5
(6
):657
–62
. 12.
Huang
CC
, Chou
W
, Lin
HJ
, Chen
SC
, Kuo
SC
, Chen
WL
, et al. Cancer history, bandemia, and serum creatinine are independent mortality predictors in patients with infection-precipitated hyperglycemic crises
. BMC Endocr Disord
. 2013
;13
:23
. 13.
Huang
CC
, Chien
TW
, Su
SB
, Guo
HR
, Chen
WL
, Chen
JH
, et al. Infection, absent tachycardia, cancer history, and severe coma are independent mortality predictors in geriatric patients with hyperglycemic crises
. Diabetes Care
. 2013
;36
(9
):e151
–2
. 14.
Kao
Y
, Hsu
CC
, Weng
SF
, Lin
HJ
, Wang
JJ
, Su
SB
, et al. Subsequent mortality after hyperglycemic crisis episode in the non-elderly: a national population-based cohort study
. Endocrine
. 2016
;51
(1
):72
–82
. 15.
Kao
Y
, Feng
IJ
, Hsu
CC
, Wang
JJ
, Lin
HJ
, Huang
CC
. Association of hyperglycemic crisis with an increased risk of end-stage renal disease: a nationwide population-based cohort study
. Diabetes Res Clin Pract
. 2018
;138
:106
–12
. 16.
Wang
JY
, Wang
CY
, Huang
YS
, Chen
PF
, Huang
KY
, Chou
P
, et al. Increased risk of ischemic stroke after hyperosmolar hyperglycemic state: a population-based follow-up study
. PLoS One
. 2014
;9
(4
):e94155
. 17.
Crane
PK
, Walker
R
, Hubbard
RA
, Li
G
, Nathan
DM
, Zheng
H
, et al. Glucose levels and risk of dementia
. N Engl J Med
. 2013
;369
(6
):540
–8
. 18.
de Oliveira
MFB
, Yassuda
MS
, Aprahamian
I
, Neri
AL
, Guariento
ME
. Hypertension, diabetes and obesity are associated with lower cognitive performance in community-dwelling elderly: data from the FIBRA study
. Dement Neuropsychol
. 2017
;11
(4
):398
–405
. 19.
National Health Insurance Research Database. Background [cited 2019 Jan 13]. Accessed from: https://nhird.nhri.org.tw/en/index.html
.20.
Cheng
CL
, Kao
YH
, Lin
SJ
, Lee
CH
, Lai
ML
. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan
. Pharmacoepidemiol Drug Saf
. 2011
;20
(3
):236
–42
. 21.
Lin
LY
, Warren-Gash
C
, Smeeth
L
, Chen
PC
. Data resource profile: the National Health Insurance Research Database (NHIRD)
. Epidemiol Health
. 2018
;40
:e2018062
. 22.
Singh-Manoux
A
, Kivimaki
M
, Glymour
MM
, Elbaz
A
, Berr
C
, Ebmeier
KP
, et al. Timing of onset of cognitive decline: results from Whitehall II prospective cohort study
. BMJ
. 2012
;344
:d7622
. 23.
Chen
YL
, Weng
SF
, Yang
CY
, Wang
JJ
, Tien
KJ
. Diabetic ketoacidosis further increases risk of Alzheimer’s disease in patients with type 2 diabetes
. Diabetes Res Clin Pract
. 2019
;147
:55
–61
.24.
Ojo
O
, Brooke
J
. Evaluating the association between diabetes, cognitive decline and dementia
. Int J Environ Res Public Health
. 2015
;12
(7
):8281
–94
. 25.
Lacy
ME
, Gilsanz
P
, Karter
AJ
, Quesenberry
CP
, Pletcher
MJ
, Whitmer
RA
. Long-term glycemic control and dementia risk in type 1 diabetes
. Diabetes Care
. 2018
;41
(11
):2339
–45
. 26.
Cui
Y
, Liang
X
, Gu
H
, Hu
Y
, Zhao
Z
, Yang
XY
, et al. Cerebral perfusion alterations in type 2 diabetes and its relation to insulin resistance and cognitive dysfunction
. Brain Imaging Behav
. 2017
;11
(5
):1248
–57
. 27.
Carlsson
CM
. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease
. J Alzheimers Dis
. 2010
;20
(3
):711
–22
. 28.
Hirabayashi
N
, Hata
J
, Ohara
T
, Mukai
N
, Nagata
M
, Shibata
M
, et al. Association between diabetes and hippocampal atrophy in elderly Japanese: the Hisayama study
. Diabetes Care
. 2016
;39
(9
):1543
–9
. 29.
Poewe
W
, Gauthier
S
, Aarsland
D
, Leverenz
JB
, Barone
P
, Weintraub
D
, et al. Diagnosis and management of Parkinson’s disease dementia
. Int J Clin Pract
. 2008
;62
(10
):1581
–7
. 30.
Aarsland
D
, Andersen
K
, Larsen
JP
, Lolk
A
, Nielsen
H
, Kragh-Sørensen
P
. Risk of dementia in Parkinson’s disease: a community-based, prospective study
. Neurology
. 2001
;56
(6
):730
–6
. 31.
Hornykiewicz
O
. Basic research on dopamine in Parkinson’s disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness
. Neurodegener Dis
. 2008
;5
(3–4
):114
–7
. 32.
Fink
A
, Haenisch
B
. Oral antidiabetic drugs and dementia risk: does treatment matter?
Neurology
. 2017
;89
(18
):1848
–9
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
